MX2019002211A - Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. - Google Patents

Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2019002211A
MX2019002211A MX2019002211A MX2019002211A MX2019002211A MX 2019002211 A MX2019002211 A MX 2019002211A MX 2019002211 A MX2019002211 A MX 2019002211A MX 2019002211 A MX2019002211 A MX 2019002211A MX 2019002211 A MX2019002211 A MX 2019002211A
Authority
MX
Mexico
Prior art keywords
neurodegenerative disorders
methods
nicotinamide riboside
pterostilbene
compositions
Prior art date
Application number
MX2019002211A
Other languages
English (en)
Inventor
Alexander Marcotulli Eric
Antonio Alminana Daniel
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of MX2019002211A publication Critical patent/MX2019002211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se describen composiciones que contienen una combinación de nicotinamida ribósido y pterostilbeno para tratar los trastornos neurodegenerativos, y métodos para tratar trastornos neurodegenerativos usando estas composiciones y sus equivalentes. Los trastornos neurodegenerativos que se pueden tratar usando estas composiciones o métodos pueden incluir la enfermedad de Parkinson, enfermedad de Huntington, la enfermedad del Alzheimer, y similares. En una realización, las composiciones que contienen una combinación de nicotinamida ribósido y pterostilbeno se pueden preparar como formulaciones orales. En algunas realizaciones, un suplemento de la dieta comprende nicotinamida ribósido y/o pterostilbeno o equivalentes.
MX2019002211A 2016-08-22 2017-08-22 Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. MX2019002211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2019002211A true MX2019002211A (es) 2019-10-30

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002211A MX2019002211A (es) 2016-08-22 2017-08-22 Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.

Country Status (11)

Country Link
US (2) US11260069B2 (es)
EP (1) EP3500267A4 (es)
JP (1) JP7132907B2 (es)
KR (1) KR20190046895A (es)
CN (2) CN109982706A (es)
AU (1) AU2017316614B2 (es)
BR (1) BR112019003579A2 (es)
CA (1) CA3034673A1 (es)
MX (1) MX2019002211A (es)
RU (1) RU2019108100A (es)
WO (1) WO2018039207A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
CN111542312A (zh) 2017-07-28 2020-08-14 老龄化控制中心股份公司 预防和逆转衰老方面的组合物和方法
EP3866811A4 (en) * 2018-10-19 2022-11-02 Disarm Therapeutics, Inc. INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN113473993A (zh) * 2019-02-26 2021-10-01 巴伦西亚大学 治疗运动神经元疾病的方法和组合物
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
AU2022299351A1 (en) * 2021-06-24 2024-01-04 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
US8933217B2 (en) 2009-07-24 2015-01-13 Amazentis Sa Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) * 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20160067195A (ko) * 2013-10-30 2016-06-13 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
WO2016122832A1 (en) 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production

Also Published As

Publication number Publication date
RU2019108100A (ru) 2020-09-22
AU2017316614A1 (en) 2019-03-21
RU2019108100A3 (es) 2020-11-27
EP3500267A4 (en) 2020-03-18
CA3034673A1 (en) 2018-03-01
JP7132907B2 (ja) 2022-09-07
CN115645432A (zh) 2023-01-31
US20220143055A1 (en) 2022-05-12
AU2017316614B2 (en) 2023-06-15
CN109982706A (zh) 2019-07-05
WO2018039207A1 (en) 2018-03-01
US20190201426A1 (en) 2019-07-04
EP3500267A1 (en) 2019-06-26
US11260069B2 (en) 2022-03-01
BR112019003579A2 (pt) 2019-05-21
KR20190046895A (ko) 2019-05-07
JP2019524856A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
MX2019002211A (es) Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2015017253A (es) Composiciones y metodos para tratar trastornos metabolicos.
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
IL277182A (en) Compositions and methods for treating parkinson's disease
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2018005312A (es) Composiciones y metodos para el tratamiento de la homocistinuria.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
WO2018128722A8 (en) Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
EP4037696A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EP3628008A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease